Monte Rosa, BioAge plunge after Novo’s setback (GLUE:NASDAQ)

Shares of Monte Rosa Therapeutics (GLUE) and BioAge Labs (BIOA) experienced significant declines after Novo Nordisk's (NVO) late-stage trial setback cast doubt on the mechanisms underlying their experimental heart disease therapies. The failure of Novo Nordisk's drug, which targeted hsCRP, raised questions about whether reducing this inflammatory marker translates into preventing major cardiovascular events. This outcome puts increased scrutiny on Monte Rosa and BioAge, which are developing similar anti-inflammatory agents.